会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明授权
    • Heterocyclic ethanolamine derivatives with .beta.-adrenoreceptor
agonistic activity
    • 具有β-肾上腺素受体激动活性的杂环乙醇胺衍生物
    • US5750701A
    • 1998-05-12
    • US704699
    • 1996-09-16
    • Lee James BeeleyDavid Kenneth Dean
    • Lee James BeeleyDavid Kenneth Dean
    • C07D215/22A61K31/41A61K31/415A61K31/4184A61K31/42A61K31/423A61K31/425A61K31/47A61K31/54A61K31/541A61K31/5415A61P1/00A61P3/04A61P3/08A61P9/10C07D235/26C07D235/28C07D263/58C07D279/02C07D291/08C07D405/12C07D215/227C07D215/36
    • C07D405/12
    • A compound of the formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, wherein, X represents a moiety of formula (a), in which A.sup.1 represents --CH.dbd.CH.dbd., NH, S or O; A.sup.2 represents an oxo or a thioxo group; A.sup.3 represents H or an alkylcarbonyl group; and A.sup.4 represents hydroxy or NR.sup.s R.sup.t wherein R.sup.s and R.sup.t each independently represents H or alkyl; R.sup.0 and R.sup.1 each independently represents hydrogen or an alkyl group; R.sup.2 represents OCH.sub.2 CO.sub.2 H, or an ester or amide thereof, or R.sup.2 represents a moiety of formula (b), wherein R.sup.4 and R.sup.5 each independently represent hydrogen, alkyl, hydroxyalkyl, cycloalkyl or R.sup.4 together with R.sup.5 represents (CH.sub.2).sub.n wherein n is 2, 3 or 4; and R.sup.3 represents hydrogen, halogen, alkyl or alkoxy or R.sup.3 together with R.sup.2 represents a moiety of formula (c) or an ester or amide thereof, wherein R represents hydrogen, alkyl, hydroxymethyl or a moiety of formula (CH.sub.2).sub.n CO.sub.2 H, wherein n is zero or an integer 1, 2 or 3, or an ester or amide thereof; a process for the preparation of such a compound, a pharmaceutical composition containing such a compound and the use of such a compound and composition in medicine.
    • PCT No.PCT / EP95 / 00794 Sec。 371日期1996年9月16日 102(e)1996年9月16日PCT PCT 1995年3月3日PCT公布。 第WO95 / 25104号公报 日期1995年9月21日一种式(I)化合物或其药学上可接受的盐或其药学上可接受的溶剂化物,其中X表示式(a)的部分,其中A1表示-CH = CH =, NH,S或O; A2表示氧代或硫代基; A3表示H或烷基羰基; 并且A4表示羟基或NRsRt,其中R 5和R 5各自独立地表示H或烷基; R 0和R 1各自独立地表示氢或烷基; R2表示OCH2CO2H,或其酯或酰胺,或R2表示式(b)的部分,其中R4和R5各自独立地表示氢,烷基,羟基烷基,环烷基或R4以及R5表示(CH2)n,其中n为2 ,3或4; 并且R 3表示氢,卤素,烷基或烷氧基或R 3与R 2一起表示式(c)的部分或其酯或酰胺,其中R表示氢,烷基,羟甲基或式(CH2)nCO2H的部分,其中n 为零或整数1,2或3,或其酯或酰胺; 制备这种化合物的方法,含有这种化合物的药物组合物以及这种化合物和组合物在医药中的用途。
    • 2. 发明授权
    • Biologically active peptide of ob protein
    • 生物活性肽的ob蛋白
    • US06187751B1
    • 2001-02-13
    • US09391799
    • 1999-09-09
    • Richard Anthony Godwin SmithLee James Beeley
    • Richard Anthony Godwin SmithLee James Beeley
    • A61K3810
    • C07K14/5759A61K38/00
    • The present invention provides a protein fragment of the ob protein, being an active site of the protein. The active site is suitably provided by the ob protein when it is in the form of a four helix bundle structure, particularly that having an up-up down-down topology. In particular, the active site is formed from one or more amino acids selected from one or more of the four helices forming the secondary stucture of the ob protein, especially a protein fragment consisting of amino acid residues 26 to 39, 74 to 88, 93 to 113 or 142 to 161. The compounds of the invention arc considered to be capable of regulating the physiological activity of the ob protein and are therefor of potential use in the treatment of nutritional and metabollic disorders, particularly obesity and diabetes in the case of agonists and anorexia and cachexia in the case of antagonists.
    • 本发明提供了作为蛋白质的活性位点的ob蛋白质的蛋白质片段。 当它是四螺旋束结构的形式时,活性位点适当地由ob蛋白质提供,特别是具有上 - 下 - 下拓扑结构的形式。 特别地,活性位点由选自形成ob蛋白的二级结构的四个螺旋中的一个或多个的一个或多个氨基酸形成,特别是由氨基酸残基26至39,74至88,93组成的蛋白质片段 至113或142至161。本发明的化合物被认为能够调节ob蛋白的生理活性,因此在治疗营养和代谢障碍,特别是肥胖症和糖尿病的情况下可能用于激动剂 而在拮抗剂的情况下,厌食症和恶病质。